Related Experiment Video
Updated: May 31, 2026
07:09
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
Published on: February 18, 2022
Prevention of heart failure
Massimo Piepoli1,2, Giuseppe Rosano3,4, Ana Abreu5,6
1Department of Biomedical Science for Health, University of Milan, Milan, Italy.
European Heart Journal
|May 30, 2026
Summary
Preventing heart failure (HF) requires a comprehensive strategy addressing comorbidities like diabetes and kidney disease. A holistic, tailored approach is crucial for managing diverse risk factors and improving patient outcomes.
Area of Science:
- Cardiology
- Preventive Cardiology
- Public Health
Background:
- Heart failure (HF) is a significant global health burden despite therapeutic advances.
- A shift in HF phenotypes, with increasing prevalence of preserved ejection fraction driven by renal and metabolic conditions, necessitates updated prevention strategies.
- Existing guidelines require augmentation with recent evidence on HF prevention, particularly concerning metabolic and renal factors.
Purpose of the Study:
- To provide an updated perspective on heart failure prevention.
- To highlight the importance of a multidisciplinary and holistic approach to managing HF risk factors.
- To incorporate recent evidence, especially regarding metabolic disorders, diabetes, and kidney diseases.
Main Methods:
- Review and synthesis of recent scientific evidence on heart failure prevention.
- Analysis of evolving HF phenotypes and associated risk factors.
- Consideration of comorbidities, lifestyle factors, and socio-economic determinants.
Main Results:
- Effective HF prevention demands a multidisciplinary strategy targeting a wide range of comorbidities and risk factors.
- Arterial hypertension, chronic kidney disease, diabetes mellitus, obesity, and dyslipidemia are key modifiable risk factors.
- Infections, vaccination, chemotherapy/radiotherapy side effects, and environmental factors also play a role.
Conclusions:
- A holistic and tailored approach is essential for effective heart failure prevention.
- Addressing metabolic and renal conditions is increasingly critical for preventing HF with preserved ejection fraction.
- Continuous updates to prevention strategies are necessary given emerging evidence.
Related Concept Videos
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:22Heart Failure Drugs: β-Blockers
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
01:22Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...